Robert Driscoll
Stock Analyst at Wedbush
(1.88)
# 3,165
Out of 4,918 analysts
156
Total ratings
30.07%
Success rate
-7.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Driscoll
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Downgrades: Neutral | $19 → $4 | $7.60 | -47.37% | 6 | Jul 22, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $27 | $11.95 | +125.94% | 1 | Jul 14, 2025 | |
| KURA Kura Oncology | Reiterates: Outperform | $36 | $6.02 | +498.50% | 9 | Jun 20, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Neutral | $4 | $1.34 | +198.51% | 11 | May 15, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Outperform | $8 → $6 | $1.15 | +421.74% | 3 | May 9, 2025 | |
| RVMD Revolution Medicines | Reiterates: Outperform | $67 | $36.63 | +82.91% | 5 | Apr 28, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Outperform | $15 → $17 | $4.81 | +253.43% | 4 | Mar 21, 2025 | |
| ARVN Arvinas | Downgrades: Neutral | $57 → $12 | $7.42 | +61.73% | 9 | Mar 12, 2025 | |
| DAWN Day One Biopharmaceuticals | Reiterates: Outperform | $32 | $6.65 | +381.20% | 6 | Feb 26, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $52 | $24.26 | +114.34% | 9 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $28 | $10.49 | +167.05% | 8 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $2.59 | +517.76% | 10 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $9.16 | +227.51% | 7 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $22 | $1.31 | +1,579.39% | 10 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $51 | $9.31 | +447.80% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.67 | +645.60% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $36 | $7.68 | +369.06% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $1.66 | +562.65% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $5.00 | +160.00% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $6.53 | +99.08% | 4 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $23.57 | +213.96% | 7 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $2.96 | +170.73% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $7 | $1.17 | +498.29% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $8 | $2.35 | +240.43% | 9 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $4 | $3.27 | +22.32% | 4 | May 19, 2020 |
Replimune Group
Jul 22, 2025
Downgrades: Neutral
Price Target: $19 → $4
Current: $7.60
Upside: -47.37%
Crescent Biopharma
Jul 14, 2025
Initiates: Outperform
Price Target: $27
Current: $11.95
Upside: +125.94%
Kura Oncology
Jun 20, 2025
Reiterates: Outperform
Price Target: $36
Current: $6.02
Upside: +498.50%
Zentalis Pharmaceuticals
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $1.34
Upside: +198.51%
Werewolf Therapeutics
May 9, 2025
Maintains: Outperform
Price Target: $8 → $6
Current: $1.15
Upside: +421.74%
Revolution Medicines
Apr 28, 2025
Reiterates: Outperform
Price Target: $67
Current: $36.63
Upside: +82.91%
Monte Rosa Therapeutics
Mar 21, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $4.81
Upside: +253.43%
Arvinas
Mar 12, 2025
Downgrades: Neutral
Price Target: $57 → $12
Current: $7.42
Upside: +61.73%
Day One Biopharmaceuticals
Feb 26, 2025
Reiterates: Outperform
Price Target: $32
Current: $6.65
Upside: +381.20%
IDEAYA Biosciences
Dec 17, 2024
Reiterates: Outperform
Price Target: $52
Current: $24.26
Upside: +114.34%
Oct 25, 2024
Reiterates: Outperform
Price Target: $28
Current: $10.49
Upside: +167.05%
Oct 8, 2024
Reiterates: Outperform
Price Target: $16
Current: $2.59
Upside: +517.76%
Oct 3, 2024
Reiterates: Outperform
Price Target: $30
Current: $9.16
Upside: +227.51%
Oct 1, 2024
Maintains: Outperform
Price Target: $25 → $22
Current: $1.31
Upside: +1,579.39%
Sep 20, 2024
Maintains: Outperform
Price Target: $85 → $51
Current: $9.31
Upside: +447.80%
Sep 20, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.67
Upside: +645.60%
Sep 18, 2024
Reiterates: Outperform
Price Target: $36
Current: $7.68
Upside: +369.06%
Aug 13, 2024
Reiterates: Outperform
Price Target: $11
Current: $1.66
Upside: +562.65%
Aug 9, 2024
Reiterates: Outperform
Price Target: $13
Current: $5.00
Upside: +160.00%
Aug 8, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $6.53
Upside: +99.08%
Aug 8, 2024
Reiterates: Outperform
Price Target: $74
Current: $23.57
Upside: +213.96%
Aug 7, 2024
Reiterates: Outperform
Price Target: $8
Current: $2.96
Upside: +170.73%
Jun 7, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.17
Upside: +498.29%
May 9, 2024
Upgrades: Outperform
Price Target: $3 → $8
Current: $2.35
Upside: +240.43%
May 19, 2020
Upgrades: Outperform
Price Target: $2 → $4
Current: $3.27
Upside: +22.32%